N
DGX icon

Nuveen’s Quest Diagnostics DGX Stock Holding History

Nuveen’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-26,000
Closed -$3K – 1144
2017
Q1 		$3K Buy
+26,000
New +$2.48M ﹤0.01% 1354

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Nuveen's DGX Position: Q1 2026 in Review

Nuveen increased its Quest Diagnostics (DGX) stake by 39% in Q1 2026, buying an estimated $25.5M and bringing the position to 465,425 shares worth $91.2M. The position accounts for 0.02% of the portfolio, ranked #420.

Nuveen first reported a position in DGX in Q2 2013 and has held it in 50 quarters since. The position peaked at $196M in Q2 2020. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Nuveen held 465,425 shares of Quest Diagnostics worth $91.2M as of Q1 2026.
  • Nuveen bought 131,391 Quest Diagnostics shares in Q1 2026, an estimated $25.5M.
  • Quest Diagnostics made up 0.02% of Nuveen's portfolio in Q1 2026, its #420 holding.
  • Nuveen first reported a position in Quest Diagnostics in Q2 2013 and has held it in 50 quarters since.
  • Nuveen's Quest Diagnostics position peaked at $196M in Q2 2020.
  • 1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.